NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 280
Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article discussing the company reads, “TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer-cell colonies in a way that will not compromise their integrity — a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more accurate identification of tumors and the development of patient-specific treatment options. The company expects this revolutionary product to hit the market by the end of the year. . . . What is unique with TumorGenesis’ state-of-the-art approach to cancer research is that the company has already developed 25 validated, ovarian, cancer-cell types that mature into uncompromised tumor colonies not only in vitro but in rats and mice too — a formidable accomplishment as 15 out of 25 cell lines represent around 90% of all ovarian cancers discovered so far, including those most virulent and deadly.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer